KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 73 filers reported holding KALA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $6,000 | -75.0% | 556 | -80.0% | 0.00% | -100.0% |
| Q1 2020 | $24,000 | +200.0% | 2,776 | +37.0% | 0.00% | +100.0% |
| Q3 2019 | $8,000 | -11.1% | 2,027 | +42.0% | 0.00% | 0.0% |
| Q2 2019 | $9,000 | -10.0% | 1,427 | +18.2% | 0.00% | 0.0% |
| Q1 2019 | $10,000 | +11.1% | 1,207 | -39.8% | 0.00% | 0.0% |
| Q4 2018 | $9,000 | +350.0% | 2,005 | +983.8% | 0.00% | – |
| Q3 2018 | $2,000 | – | 185 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |